Top 5 RNA Therapeutics and Vaccines Shaping the Biopharmaceutical Industry

Published: August 2026

Over the past decade, RNA-based therapeutics and vaccines have emerged as a transformative class of medical innovations, owing to their central role in regulating gene expression and protein synthesis. These modalities have unlocked new possibilities in targeting a wide spectrum of diseases. Their high specificity and therapeutic efficiency position them as a promising alternative to conventional treatment approaches across multiple indications.

Despite their potential, traditional RNA-based therapies face a critical limitation of molecular instability. The inherent structural vulnerability of RNA, particularly the presence of exposed terminal ends, makes it highly susceptible to rapid degradation by exonucleases. This instability has historically posed significant challenges in ensuring effective delivery and sustained therapeutic action. To address these limitations, the industry is increasingly shifting its focus toward next generation RNA therapeutics market. These advanced modalities are engineered to overcome stability concerns through innovative structural and functional enhancements. Features such as closed-loop configurations and self-amplifying capabilities not only improve molecular stability but also enhance therapeutic efficacy and durability.

The growing interest in this space is reflected in the expanding pipeline activity. Currently, nearly 35 developers are active in the RNA therapeutics and RNA vaccines domain, with a growing focus on emerging RNA-based approaches for rare diseases and oncology. In rare diseases, RNA technologies such as antisense oligonucleotides, small interfering RNA (siRNA), messenger RNA, and RNA editing platforms are being explored to address previously undruggable genetic targets, including inherited metabolic disorders, neuromuscular diseases, and rare genetic conditions. In cancer, next-generation RNA therapies, including personalized mRNA cancer vaccines, RNA-based immunotherapies, and tumor-targeting RNA platforms, are gaining momentum due to their potential to stimulate immune responses and enable precision treatment strategies.

Notably, several candidates across infectious diseases, rare diseases, and oncology are progressing through late-stage clinical trials and are expected to achieve regulatory approvals within the next decade, signaling a strong future outlook for these technologies. Further, the market is witnessing a surge in strategic collaborations, licensing agreements, and funding initiatives aimed at accelerating innovation and commercialization. Stakeholders across the pharmaceutical and biotechnology sectors are investing heavily in advancing key aspects of RNA technology, including molecular design, delivery systems, and scalable manufacturing processes. These efforts are critical to improving the overall success rates, safety profiles, and clinical viability of RNA-based therapies, thereby driving growth across the broader RNA therapeutics market.

Roots Analysis has conducted an exhaustive study of the featuring the RNA therapeutics current market landscape and future opportunities for developers engaged in healthcare, over the span of next 9 years.

Top RNA Therapeutics and Vaccines

Kostaive®
Gemcovac®
BNT161
VLPCOV-01
AVX901

The figure below highlights the top four RNA therapeutics and vaccines:

Top RNA Therapeutics and RNA Vaccines Market

Interested in exploring all 100+ RNA therapeutics and vaccines, along with their recent initiatives?

Discover Below the Details of Top 5 RNA Therapeutics and Vaccines

Let us dive deep into the details of the top 5 RNA therapeutics and vaccines Market. It is essential to note that the selection of RNA therapeutics and vaccines can differ substantially according to the defined criteria.

1. Kostaive®

The section provides information on various parameters, with details on list of developer, type of modality, phase of development, type of molecule, route of administration, technology / platform and target indication.

Developer: Arcturus Therapeutics
Type of Modality: Vaccine
Phase of Development: Approved
Type of Molecule: saRNA
Route of Administration: Intramuscular
Technology / Platform: STARRâ„¢ mRNA Technology
Target Indication: COVID-19

To know more about the recent initiatives of Kostaive® and other RNA therapeutics and vaccines, access full report.

2. Gemcovac®

Developer: HDT Bio
Type of Modality: Vaccine
Phase of Development: Emergency Use Approval
Type of Molecule: saRNA
Route of Administration: Intramuscular
Technology / Platform: AMPLIFY Vaccine Platform
Target Indication: COVID-19

To know more about the recent initiatives of Gemcovac® and other RNA therapeutics and vaccines, access full report.

3. BNT161

Developer: BioNTech
Type of Modality: Vaccine
Phase of Development: Phase III
Type of Molecule: saRNA
Route of Administration: Intramuscular
Target Indication: Seasonal influenza

To know more about the recent initiatives of BNT161 and other RNA therapeutics and vaccines, access full report.

4. VLPCOV-01

Developer: VLP Therapeutics
Type of Modality: Vaccine
Phase of Development: Phase III
Type of Molecule: saRNA
Route of Administration: Intramuscular
Technology / Platform: Replicon Platform Technology
Target Indication: COVID-19

To know more about the recent initiatives of VLPCOV-01 and other RNA therapeutics and vaccines, access full report.

5. AVX901

Developer: Alphavax
Type of Modality: Vaccine
Phase of Development: Phase II
Type of Molecule: saRNA
Route of Administration: Intramuscular
Technology / Platform: The Alphavaccine Platform System
Target Indication: Breast Cancer

To know more about the recent initiatives of AVX901 and other RNA therapeutics and vaccines, access full report.

What About Other RNA Therapeutics and Vaccines Around the World?

The above article features the RNA therapeutics and vaccines selected from a pool of over 100 RNA therapeutics and vaccines that we have compiled. If you're interested, you can download the on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at .